ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH

Key Takeaways ALT received FDA Breakthrough Therapy Designation for pemvidutide in MASH, boosting shares by 16.52%.The tag is backed by IMPACT data, showing MASH resolution without worsening fibrosis & improved liver markers.ALT plans to begin a phase III MASH study in 2026.Altimmune (ALT) announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide, a novel, investigational GLP-1/glucagon dual receptor agonist, for the treatment of patients with metabolic ...